Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06255028 · ClinicalTrials.gov registry record · Phase 1
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
A Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Century Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 6
- Study locations
NCT06255028: Active Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Century Therapeutics.
NCT06255028 is a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis that is active but no longer recruiting, run by Century Therapeutics. The registered enrollment target is 6 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06255028, a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, is active but no longer recruiting, sponsored by Century Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 6
- Study locations
Study Summary
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
Conditions Studied
Interventions
- BIOLOGICAL CNTY-101
- BIOLOGICAL IL-2
- DRUG Lymphodepleting Chemotherapy
Study Locations (6)
California
- Keck School of Medicine of University of Southern California - Los Angeles
- UC Davis - Sacramento
Illinois
- Lurie Children's; Northwestern Medicine - Northwestern Medical Group - Chicago
Texas
- Texas Children's Hospital - Houston
Utah
- Primary Children's Hospital - Salt Lake City
Washington
- Fred Hutch - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What the registry record for NCT06255028 still lists
NCT06255028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 3 interventions - of which CNTY-101 is the first listed.
NCT06255028 lists 6 locations in 5 states (California, Illinois, Texas).
Frequently Asked Questions
What is clinical trial NCT06255028 about?
NCT06255028 is a clinical study titled "A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases". CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathi...
What is the current status of trial NCT06255028?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-02-06. Estimated completion is 2028-08.
What conditions does trial NCT06255028 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis.
What interventions are being tested in trial NCT06255028?
The interventions under investigation include: CNTY-101 (BIOLOGICAL), IL-2 (BIOLOGICAL), Lymphodepleting Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT06255028?
This trial is sponsored by Century Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06255028 being conducted?
This trial has 6 study locations across California, Illinois, Texas, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06255028's enrollment target sits among peer trials
6 99th of 99 the lowest of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI